MCID: OCL010
MIFTS: 37

Ocular Hypotension

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Ocular Hypotension

MalaCards integrated aliases for Ocular Hypotension:

Name: Ocular Hypotension 12 44 15 71
Hypotony of Eye 12 32

Classifications:



External Ids:

Disease Ontology 12 DOID:790
ICD9CM 34 360.3
MeSH 44 D015814
SNOMED-CT 67 23670006
ICD10 32 H44.4
UMLS 71 C0028841

Summaries for Ocular Hypotension

MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and cataract, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Latanoprost and Travoprost have been mentioned in the context of this disorder. Affiliated tissues include eye and retina.

Related Diseases for Ocular Hypotension

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension

Symptoms & Phenotypes for Ocular Hypotension

UMLS symptoms related to Ocular Hypotension:


eye manifestations

Drugs & Therapeutics for Ocular Hypotension

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
2
Travoprost Approved Phase 4 157283-68-6 5282226
3
Timolol Approved Phase 4 26839-75-8 33624 5478
4
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
5 Antihypertensive Agents Phase 4
6 Anti-Arrhythmia Agents Phase 4
7 Adrenergic Antagonists Phase 4
8 Adrenergic beta-Antagonists Phase 4
9 Adrenergic Agents Phase 4
10 Neurotransmitter Agents Phase 4
11
Dorzolamide Approved Phase 3 120279-96-1 3154 5284549
12
Maleic acid Experimental Phase 3 110-16-7 444266
13 Ophthalmic Solutions Phase 3
14 Pharmaceutical Solutions Phase 3
15 Carbonic Anhydrase Inhibitors Phase 3
16
Lidocaine Approved, Vet_approved 137-58-6 3676
17
Dexmedetomidine Approved, Vet_approved 113775-47-6 68602 5311068
18
Bupivacaine Approved, Investigational 38396-39-3, 2180-92-9 2474
19 Anesthetics
20 Adrenergic alpha-Agonists
21 Analgesics, Non-Narcotic
22 Hypnotics and Sedatives
23 Anesthetics, Local
24 Analgesics
25 Adrenergic Agonists

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures Completed NCT00329095 Phase 4 travoprost, latanoprost, or bimatoprost;Additional ocular hypotensive medication
2 A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma Completed NCT00913029 Phase 4 latanoprost/timolol
3 Ocular Hypertension Treatment Study (OHTS) Completed NCT00000125 Phase 3 Topical ocular hypotensive eye drops.
4 A Prospective, Double-masked, Randomized, Multi-center, Active Controlled, Parallel-group, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution 0.02% and Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure Completed NCT02674854 Phase 3 PG324 Ophthalmic Solution 0.02%/0.005%;Netarsudil (AR-13324) ophthalmic solution 0.02%;Latanoprost ophthalmic solution 0.005%
5 A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects With Elevated Intraocular Pressure Completed NCT02558400 Phase 3 PG324 Ophthalmic Solution 0.02%/0.005%;Netarsudil (AR-13324) Ophthalmic Solution 0.02%;Latanoprost Ophthalmic Solution 0.005%
6 Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension Completed NCT00108017 Phase 3 MK0507A, dorzolamide hydrochloride (+) timolol maleate;Comparator: timolol maleate;Duration of Treatment: Part 1) 6 wk timolol maleate run in;Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds
7 A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure Completed NCT02558374 Phase 3 AR-13324 Ophthalmic Solution 0.02%;Timolol Maleate Ophthalmic Solution 0.5% BID
8 A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure Completed NCT02207621 Phase 3 AR-13324 Ophthalmic Solution 0.02%;Timolol maleate Ophthalmic Solution 0.5% BID;AR-13324 Ophthalmic Solution 0.02% BID
9 A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3) Completed NCT03284853 Phase 3 Netarsudil/Latanoprost 0.02%/0.005%;GANFORT®
10 A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure Completed NCT02207491 Phase 3 Timolol maleate Ophthalmic Solution 0.5% BID;AR-13324 Ophthalmic Solution 0.02%
11 A Phase 2, Double-masked, Randomized, Active-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure Completed NCT01060579 Phase 2 AR-12286 0.5% ophthalmic solution;AR-12286 0.25% Ophthalmic solution;Latanoprost ophthalmic solution
12 A Phase 2 Open Label Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT01330979 Phase 2 AR-12286 0.5% Ophthalmic Solution
13 A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure Completed NCT01474135 Phase 2 0.25% AR-12286 / 0.004% travoprost;0.5% AR-12286, 0.004% travoprost;0.004% Travoprost
14 A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost Completed NCT01302249 Phase 2 Latanoprost 0.005%;AR-12286 Ophthalmic Solution 0.5%;Timolol maleate ophthalmic solution 0.5%
15 A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure Completed NCT01731002 Phase 2 AR-13324 Ophthalmic Solution 0.01%;AR-13324 Ophthalmic Solution 0.02%;Latanoprost ophthalmic solution 0.005%
16 A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT02129673 Phase 1, Phase 2 VS101 Insert Dose A;VS101 Insert Dose B;VS101 Insert Dose C;Latanoprost 0.005% eye drops
17 A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure Completed NCT02057575 Phase 2 PG324 Ophthalmic Solution 0.01%;PG324 Ophthalmic Solution 0.02%;Netarsudil (AR-13324) Ophthalmic Solution 0.02%;Latanoprost Ophthalmic Solution 0.005%
18 A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States Completed NCT03310580 Phase 2 AR-13324 Ophthalmic Solution 0.02%;AR-13324 Ophthalmic Solution 0.04%;AR-13324 Ophthalmic Solution Placebo
19 A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components Completed NCT01789736 Phase 2 PG286 Ophthalmic Solution 0.5%;AR-12286 Ophthalmic Solution 0.5%;Travoprost Ophthalmic Solution 0.004%
20 A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of Three Doses of AR-13324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure Completed NCT01528787 Phase 2 AR-13324 Ophthalmic Solution 0.01%;AR-13324 Ophthalmic Solution 0.02%;AR-13324 Ophthalmic Solution 0.04%
21 A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan Completed NCT03844945 Phase 2 Netarsudil Ophthalmic Solution 0.01%;Netarsudil Ophthalmic Solution 0.02%;Netarsudil Ophthalmic Solution 0.04%
22 A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure Completed NCT00902200 Phase 2 AR-12286;AR-12286 vehicle
23 A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure Completed NCT00523250 Phase 2 AR-102 0.003% Ophthalmic Solution;AR-102 0.005% Ophthalmic Solution;AR-102 0.01% Ophthalmic Solution;AR-102 0.03% Ophthalmic Solution;AR-102 Vehicle Ophthalmic Solution
24 The Effect of Trabeculectomy, Glaucoma Drainage Device, Cyclophotocoagulation, and Ocular Hypotensive Eye-drops on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma Unknown status NCT02868502
25 A Prospective, Randomized, Controlled, Parallel Groups Evaluation of Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty Unknown status NCT01444105
26 Effect of Hyaluronidase on Intraocular Pressure After Retrobulbar Anaesthesia During Cataract Surgery Unknown status NCT03266406 Hyaluronidase
27 Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery Unknown status NCT02846090 Dexmedetomidine to reduce the IOP
28 Clinical Evaluation of CATS Tonometer Prism Completed NCT02990169
29 A Prospective Evaluation of the Second Generation iStent Inject in Open-Angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications Recruiting NCT03478293

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Genetic Tests for Ocular Hypotension

Anatomical Context for Ocular Hypotension

MalaCards organs/tissues related to Ocular Hypotension:

40
Eye, Retina

Publications for Ocular Hypotension

Articles related to Ocular Hypotension:

(show top 50) (show all 190)
# Title Authors PMID Year
1
Optic Disc Edema and Posterior Globe Flattening Secondary to Ocular Hypotony: Case Report and Discussion Regarding Pathophysiology and Clinical Findings. 61
33105416 2020
2
Evidence on the neuroprotective properties of brimonidine in glaucoma. 61
32988470 2020
3
Modified Intraocular Lens Intrascleral Fixation Technique Using Two Vitrectomy Ports as Lens Haptic Fixation Sites. 61
32440088 2020
4
Treatment of chronic and extreme ocular hypotension following glaucoma surgery with intraocular platelet-rich plasma: A case report. 61
30295074 2019
5
Use of Intravitreal Injection of Gentamicin in 71 Horses With Equine Recurrent Uveitis. 61
31133325 2019
6
The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors. 61
30341781 2019
7
RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis. 61
30456419 2019
8
SILICONE MICROTUBE-ASSISTED SCLERAL FIXATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS. 61
29561385 2018
9
Bilateral corneal denting after surgery under general anesthesia: A case report. 61
29780956 2018
10
Traumatic cyclodialysis treated with transscleral ciclodiode laser: Anterior and posterior segment evolution. 61
28532619 2017
11
[Ocular Hypotension: How the Retina Surgeon Sees the Causes and Therapeutic Options]. 61
27617647 2016
12
[Postoperative Follow-Up of Glaucoma Drainage Devices]. 61
27187881 2016
13
Induction of Functional 3D Ciliary Epithelium-Like Structure From Mouse Induced Pluripotent Stem Cells. 61
26780319 2016
14
Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea. 61
26031663 2015
15
[Channelography and mechanism of action in canaloplasty]. 61
25833753 2015
16
Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. 61
24583339 2014
17
Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months. 61
25061275 2014
18
Patient satisfaction with topical ocular hypotensives. 61
22594958 2013
19
Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes. 61
23966769 2013
20
Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma. 61
22178719 2012
21
Clinical study on Hypotony following blunt ocular trauma. 61
23275915 2012
22
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. 61
21434594 2010
23
[Uveitis in juvenile idiopathic arthritis]. 61
20532786 2010
24
[Advantages and disadvantages of heavy silicone oil]. 61
20532517 2010
25
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. 61
20148660 2010
26
Evaluation of monkey intraocular pressure by rebound tonometer. 61
19898690 2009
27
Prolonged ocular hypotension: would ciliary tissue transplantation help. 61
19098698 2009
28
Acute effects of intravenously administered ethanol on retinal vessel diameters and flicker induced vasodilatation in healthy volunteers. 61
19523476 2009
29
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. 61
19234340 2009
30
Latanoprost-induced changes in rat intraocular pressure: direct or indirect? 61
18665807 2008
31
[Clinical characteristics of occult scleral rupture]. 61
18953899 2008
32
Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits. 61
17239401 2007
33
Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. 61
17284931 2007
34
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. 61
17238805 2006
35
Effect of beta radiation on success of glaucoma drainage surgery in South Africa: randomised controlled trial. 61
17023435 2006
36
Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog. 61
17076623 2006
37
[Vogt-Koyanagi-Harada disease. Characteristics of a series of Andalusian patients]. 61
16863625 2006
38
Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. 61
16289049 2006
39
Effects of travoprost 0.004% compared with latanoprost 0.005% on the intraocular pressure of normal dogs. 61
16497237 2006
40
Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. 61
16534251 2006
41
Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl)adenosine or 2-(6-cyano-1-hexyn-1-yl)adenosine. 61
15821340 2005
42
Fadolmidine-induced ocular hypotension in normotensive rabbits. 61
15720782 2005
43
[Role of adenosine in intraocular pressure]. 61
15056945 2004
44
Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits. 61
14985053 2004
45
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. 61
15006155 2004
46
Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. 61
14711725 2004
47
[Ocular complications of the virostatic drug cidofovir]. 61
12830392 2003
48
[Ultrasonic biomicroscopic findings after spontaneous resolution of a traumatic cyclodialysis]. 61
12743845 2003
49
Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites. 61
12438531 2002
50
Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. 61
12537677 2002

Variations for Ocular Hypotension

Expression for Ocular Hypotension

Search GEO for disease gene expression data for Ocular Hypotension.

Pathways for Ocular Hypotension

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 PDE4D PDE4C PDE4B PDE4A HTR2B ADRB2
2
Show member pathways
12.79 PDE4D PDE4C PDE4B PDE4A ADRB2 ADRB1
3
Show member pathways
12.77 PDE4D PDE4C PDE4B PDE4A
4
Show member pathways
12.51 PDE4D PDE4C PDE4B PDE4A
5 12.31 PDE4B ADRB2 ADRB1
6
Show member pathways
12.28 PDE4D PDE4C PDE4B PDE4A ADORA1
7
Show member pathways
12.27 PDE4D PDE4B ADRB2 ADRB1
8
Show member pathways
12.26 ADRB2 ADRB1 ADORA1
9
Show member pathways
12.15 PDE4D PDE4C PDE4B PDE4A ADRB2
10 12.12 HTR2B ADRB2 ADRB1
11
Show member pathways
12.1 PDE4A ADRB2 ADRB1
12 11.79 PDE4B ADRB2 ADRB1
13
Show member pathways
11.71 HTR2B ADRB2 ADRB1
14 11.65 PDE4D PDE4C PDE4B PDE4A
15 11.6 PDE4D PDE4C PDE4B PDE4A ADRB2 ADRB1
16 11.5 PDE4D PDE4C PDE4B PDE4A ADRB2 ADRB1
17 11.47 ADRB2 ADRB1 ADORA1
18
Show member pathways
11.42 PDE4D PDE4C PDE4B PDE4A
19 11.36 ADRB2 ADRB1 ADORA1
20 11.34 ADRB2 ADRB1
21 10.91 ADRB2 ADRB1

GO Terms for Ocular Hypotension

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.26 PDE4D PDE4C PDE4B PDE4A
2 voltage-gated calcium channel complex GO:0005891 8.62 PDE4D PDE4B

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.86 PDE4D PDE4C PDE4B PDE4A HTR2B ADRB2
2 cellular response to drug GO:0035690 9.58 PDE4B PDE4A
3 positive regulation of interferon-gamma production GO:0032729 9.58 PDE4D PDE4B
4 activation of adenylate cyclase activity GO:0007190 9.57 ADRB2 ADRB1
5 response to cold GO:0009409 9.56 ADRB2 ADRB1
6 G protein-coupled receptor signaling pathway GO:0007186 9.56 PDE4D PDE4C PDE4B PDE4A HTR2B ADRB2
7 positive regulation of interleukin-2 production GO:0032743 9.55 PDE4D PDE4B
8 brown fat cell differentiation GO:0050873 9.54 ADRB2 ADRB1
9 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.52 ADRB2 ADRB1
10 cellular response to epinephrine stimulus GO:0071872 9.51 PDE4D PDE4B
11 adrenergic receptor signaling pathway GO:0071875 9.49 PDE4D ADRB2
12 diet induced thermogenesis GO:0002024 9.48 ADRB2 ADRB1
13 negative regulation of multicellular organism growth GO:0040015 9.46 ADRB2 ADRB1
14 negative regulation of heart contraction GO:0045822 9.43 PDE4D ADORA1
15 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.4 ADRB2 ADRB1
16 negative regulation of relaxation of cardiac muscle GO:1901898 9.37 PDE4D PDE4B
17 regulation of cardiac muscle cell contraction GO:0086004 9.33 PDE4D PDE4B ADORA1
18 heat generation GO:0031649 9.32 ADRB2 ADRB1
19 cAMP catabolic process GO:0006198 8.92 PDE4D PDE4C PDE4B PDE4A

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.67 HTR2B ADRB2 ADRB1 ADORA1
2 phosphoric diester hydrolase activity GO:0008081 9.46 PDE4D PDE4C PDE4B PDE4A
3 cAMP binding GO:0030552 9.43 PDE4D PDE4B PDE4A
4 adrenergic receptor activity GO:0004935 9.32 ADRB2 ADRB1
5 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.26 PDE4D PDE4C PDE4B PDE4A
6 3',5'-cyclic-AMP phosphodiesterase activity GO:0004115 8.92 PDE4D PDE4C PDE4B PDE4A

Sources for Ocular Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....